Published in Clin Pharmacol Ther on March 01, 1988
Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol (2005) 0.90
The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration. Br J Clin Pharmacol (1989) 0.88
Therapeutic drug monitoring in saliva. Clin Pharmacokinet (1978) 2.66
The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol (1996) 2.34
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology (1979) 2.31
Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation (1992) 2.15
Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol (1983) 1.78
Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics. Br J Clin Pharmacol (1979) 1.75
The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev (1997) 1.73
Captopril-associated agranulocytosis. Lancet (1980) 1.61
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol (1984) 1.60
Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet (1982) 1.57
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol (1979) 1.55
Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther (1982) 1.51
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther (2007) 1.47
Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet (1991) 1.46
Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth (2005) 1.44
Effect of propofol on peripheral vascular resistance during cardiopulmonary bypass. Br J Anaesth (1990) 1.44
Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol (1982) 1.43
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther (1992) 1.41
Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth (2006) 1.41
Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther (1987) 1.41
Modeling and simulation at the interface of nonclinical and early clinical drug development. CPT Pharmacometrics Syst Pharmacol (2013) 1.40
Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr (1983) 1.39
Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev (2000) 1.37
Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica (1979) 1.37
An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet (1997) 1.37
Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol (1975) 1.35
Clinical pharmacokinetics of hypnotics. Clin Pharmacokinet (1977) 1.32
Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet (1983) 1.32
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther (1984) 1.32
Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology (1998) 1.30
A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther (2010) 1.30
Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci (2001) 1.26
Assay of triazolam in plasma by capillary gas chromatography. J Chromatogr (1981) 1.22
Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. Acta Med Scand (1978) 1.19
Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther (1991) 1.16
Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci (Lond) (1981) 1.14
Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet (1977) 1.14
A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther (1991) 1.14
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev (1997) 1.13
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol (1982) 1.13
Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development. Clin Pharmacol Ther (2011) 1.12
Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther (1980) 1.12
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. J Pharmacol Exp Ther (1998) 1.11
Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol (1988) 1.11
Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm. Clin Pharmacokinet (1997) 1.11
Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet (1982) 1.11
Influence of sex and oral contraceptive steroids on antipyrine metabolite formation. Clin Pharmacol Ther (1982) 1.10
Pharmacokinetics of benzodiazepines. Short-acting versus long-acting. Arzneimittelforschung (1980) 1.10
Identification of vascular postsynaptic alpha 1- and alpha 2-adrenoceptors in man. Circ Res (1984) 1.09
Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine. J Chromatogr (1984) 1.07
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther (1995) 1.06
Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. Clin Pharmacol Ther (1977) 1.06
Pharmacokinetics of temazepam compared with other benzodiazepine hypnotics--some clinical consequences. Acta Psychiatr Scand Suppl (1986) 1.06
Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) (2005) 1.06
The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol (1999) 1.05
Pharmacokinetics of methohexitone following intravenous infusion in humans. Br J Anaesth (1976) 1.05
Arterial thromboembolic complications with aortic ball valve prostheses. Am Heart J (1978) 1.04
Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol (1988) 1.04
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther (1994) 1.04
Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro. J Pharmacol Exp Ther (1996) 1.03
Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther (1989) 1.03
Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther (1988) 1.02
Eicosanoid production by rat cerebral endothelial cells: stimulation by lipopolysaccharide, interleukin-1 and interleukin-6. J Neuroimmunol (1995) 1.01
Modulation of noradrenaline release by peripheral presynaptic alpha 2-adrenoceptors in humans. J Cardiovasc Pharmacol (1987) 1.01
Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. Br J Clin Pharmacol (1983) 1.01
Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect. J Pharmacol Exp Ther (1984) 1.00
Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res (2000) 1.00
Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet (1992) 0.99
Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit (1994) 0.99
Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther (1985) 0.99
From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs. Clin Pharmacol Ther (2009) 0.99
Partial agonism of theophylline-7-riboside on adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.99
Regional vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension (1988) 0.99
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther (1998) 0.99
Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol (1996) 0.98
Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol (1983) 0.98
Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther (1987) 0.98
Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther (1988) 0.97
Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension. Eur J Clin Pharmacol (1982) 0.97
Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res (1998) 0.97